Form 8-K - Current report:
SEC Accession No. 0000950170-21-000408
Filing Date
2021-06-30
Accepted
2021-06-30 08:46:05
Documents
12
Period of Report
2021-06-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K rare-20210629.htm   iXBRL 8-K 46885
  Complete submission text file 0000950170-21-000408.txt   161805

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20210629_lab.xml EX-101.LAB 12936
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20210629.xsd EX-101.SCH 2447
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20210629_pre.xml EX-101.PRE 9595
5 EXTRACTED XBRL INSTANCE DOCUMENT rare-20210629_htm.xml XML 4522
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 211060512
SIC: 2834 Pharmaceutical Preparations